Shahsavari Gholamreza et al. Genetic associations and serum paraoxonase levels with atherosclerosis in western Iranian patients. (2020) MOLECULAR BIOLOGY REPORTS 0301-4851 1573-4978 47 7 5137-5144
Rastegar Shandokht et al. Evaluation association between PON1 Q192R gene Polymorphisms with Arylesterase activity and plasma level Malondialdehyde in infertile man. (2019) MEDICAL SCIENCE 2321-7359 23 97 327-332
Eroglu Eray et al. Serum paraoxonase activity is associated with epicardial fat tissue in renal transplant recipients. (2015) INTERNATIONAL UROLOGY AND NEPHROLOGY 0301-1623 1573-2584 47 8 1409-1414
Sarioglu N et al. Paraoxonase 1 phenotype and paraoxonase activity in asthmatic patients. (2015) IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY 1735-1502 1735-5249 14 1 60-66
Bounafaa Abdelghani et al. Association between Paraoxonase 1 (PON1) Polymorphisms and the Risk of Acute Coronary Syndrome in a North African Population. (2015) PLOS ONE 1932-6203 1932-6203 10 8
Seifirad S et al. Effects of extremely low frequency electromagnetic fields on paraoxonase serum activity and lipid peroxidation metabolites in rat. (2014) JOURNAL OF DIABETES AND METABOLIC DISORDERS 2251-6581 13 1
Kahvecioglu S et al. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant. (2014) EXPERIMENTAL AND CLINICAL TRANSPLANTATION 1304-0855 12 4 334-342
Ari Elif et al. Cinacalcet may improve oxidative DNA damage in maintenance hemodialysis patients: an observational study. (2014) INTERNATIONAL UROLOGY AND NEPHROLOGY 0301-1623 1573-2584 46 9 1843-1849
Gilca Marilena et al. A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. (2014) PSYCHOPHARMACOLOGY 0033-3158 1432-2072 231 24 4703-4710
Lahrach H et al. Association of apolipoprotein E gene polymorphism with end-stage renal disease and hyperlipidemia in patients on long-term hemodialysis. (2014) RENAL FAILURE 0886-022X 1525-6049 36 10 1504-1509
Gungor O et al. Paraoxonase 1, atherosclerosis and arterial stiffness in renal patients. (2013) INTERNATIONAL UROLOGY AND NEPHROLOGY 0301-1623 1573-2584 45 2 441-447
Ghorbanihaghjo A et al. Effect of fish oil supplements on serum paraoxonase activity in female patients with rheumatoid arthritis: A double-blind randomized controlled trial. (2012) ARCHIVES OF IRANIAN MEDICINE 1029-2977 15 9 549-552
Gugliucci A et al. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. (2011) CLINICAL CHEMISTRY AND LABORATORY MEDICINE 1434-6621 1437-4331 49 1 61-67
Etemadi J et al. Renal artery stenosis in kidney transplants: Assessment of the risk factors. (2011) VASCULAR HEALTH AND RISK MANAGEMENT 1176-6344 1178-2048 7 1 503-507
Eren SH et al. Paraoxonase levels in acute mushroom poisoning cases treated in emergency department. (2011) JOURNAL OF MEDICINAL PLANTS RESEARCH 1996-0875 5 1 141-143
Kotani K et al. Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease. (2011) JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY 1138-7548 67 3 437-441
Emre H et al. Comparison of the Oxidant-Antioxidant Parameters and Sialic Acid Levels in Renal Transplant Patients and Peritoneal Dialysis Patients. (2011) TRANSPLANTATION PROCEEDINGS 0041-1345 43 3 809-812
Johnson-Davis KL et al. Blood Enzymes and Oxidative Stress in Chronic Kidney Disease: A Cross Sectional Study. (2011) ANNALS OF CLINICAL AND LABORATORY SCIENCE 0091-7370 1550-8080 41 4 331-339
Arslan C et al. The Role of Oxidative Stress and Antioxidant Defenses in Buerger Disease and Atherosclerotic Peripheral Arterial Occlusive Disease. (2010) ANNALS OF VASCULAR SURGERY 0890-5096 24 4 455-460
Font R et al. Is there a relationship between cystatin C and inflammatory status, oxidative stress and other cardiovascular risk factors in non-diabetic patients with chronic renal disease?. (2009) NEFROLOGIA 0211-6995 1989-2284 29 3 228-235
Fassett RG et al. Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients - an observational study. (2009) BMC NEPHROLOGY 1471-2369 10
Cetinalp-Demircan P et al. Adiponectin Is a Link Among Inflammation, Insulin Resistance, and High-Density Lipoprotein Cholesterol But Is Not Associated With Paraoxonase Activity in Premenopausal Women. (2009) JOURNAL OF CLINICAL HYPERTENSION 1524-6175 11 11 672-677
Lahrach H et al. Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. (2008) JOURNAL OF CLINICAL LIPIDOLOGY 1933-2874 2 1 43-50
Cakatay U et al. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. (2008) CLINICAL AND EXPERIMENTAL MEDICINE 1591-8890 1591-9528 8 1 51-57
Saeed SA et al. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. (2008) HEMODIALYSIS INTERNATIONAL 1492-7535 1542-4758 12 4 471-479
Atamer A et al. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. (2008) JOURNAL OF NEPHROLOGY 1121-8428 21 6 924-930
Fassett RG et al. Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial. (2008) BMC NEPHROLOGY 1471-2369 9
Miyoshi M et al. Gene delivery of paraoxonase-1 inhibits neointimal hyperplasia after arterial balloon-injury in rabbits fed a high-fat diet. (2007) HYPERTENSION RESEARCH 0916-9636 1348-4214 30 1 85-91
Cherki M et al. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. (2007) EXPERIMENTAL GERONTOLOGY 0531-5565 1873-6815 42 8 815-824
Marsillach J et al. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. (2007) CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY 0305-1870 1440-1681 34 4 347-349
Jurek A et al. LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. (2006) CLINICAL BIOCHEMISTRY 0009-9120 39 1 19-27
Rodriguez-Esparragon F et al. Concerning the significance of paraoxonase-1 and SR-B1 genes in atherosclerosis. (2006) REVISTA ESPANOLA DE CARDIOLOGIA 0300-8932 1579-2242 59 2 154-164
Voshol H et al. Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. (2005) JOURNAL OF PROTEOME RESEARCH 1535-3893 1535-3907 4 4 1192-1199
Ghorbanihaghjo A et al. Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients. (2005) CLINICAL BIOCHEMISTRY 0009-9120 38 12 1076-1080
Başkol M et al. A new marker for lipid peroxidation: Serum paraoxonase activity in non-alcoholic steatohepatitis. (2005) TURKISH JOURNAL OF GASTROENTEROLOGY 1300-4948 16 3 119-123
Blackhall ML et al. The relationship between antioxidant supplements and oxidative stress in renal transplant recipients: A review. (2004) ASAIO JOURNAL 1058-2916 50 5 451-457
Liberopoulos EN et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. (2004) PERITONEAL DIALYSIS INTERNATIONAL 0896-8608 24 6 580-589
Romic Z et al. Paraoxonase activity and concentration of indicators of lipids status in the serum of cardiac patients. (2003) COLLEGIUM ANTROPOLOGICUM 0350-6134 27 93-100
Polat MF et al. In vitro esterase activity of carbonic anhydrase on total esterase activity level in serum. (2002) TURKISH JOURNAL OF MEDICAL SCIENCES 1300-0144 1303-6165 32 4 299-302
Dent SB et al. Soy protein intake by perimenopausal women does not affect circulating lipids and lipoproteins or coagulation and fibrinolytic factors. (2001) JOURNAL OF NUTRITION 0022-3166 1541-6100 131 9 2280-2287
Mehrotra R et al. Nutritional management of maintenance dialysis patients: Why aren't we doing better?. (2001) ANNUAL REVIEW OF NUTRITION 0199-9885 1545-4312 21 343-379
Glassock RJ. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Opinion. (2000) SEMINARS IN DIALYSIS 0894-0959 1525-139X 13 3 167-169
Paragh György et al. Effect of gemfibrozil on HDL-Associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia. (2000) CLINICAL DRUG INVESTIGATION 1173-2563 19 4 277-282,
2971781
Marathe Aradhana et al. Effect of Atorvastatin on Serum Para-Oxonase-1 and C-Reactive Protein in Wistar Rats. (2019) INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY 0970-1915 0974-0422 34 3 312-317
Saheblear Amirhossein et al. Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status. (2016) METABOLISM-CLINICAL AND EXPERIMENTAL 0026-0495 1532-8600 65 5 609-622
Yildirim CH et al. Investigation of the effects of alpha lipoic acid application on total antioxidant and oxidant status, paraoxonase, and total sialic acid levels in laminectomized rabbits. (2014) KAFKAS UNIVERSITESI VETERINER FAKULTESI DERGISI 1300-6045 1309-2251 20 1 111-116
Yalcinkaya E et al. Association of carotid intima-media thickness and serum paraoxonase activity. (2014) EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 1128-3602 18 12 1686-1686
Bokolombe A. A. et al. Evidence for association between paraoxonase-1 activity and diseases. (2013) AFRICAN HEALTH SCIENCES 1680-6905 1729-0503 13 1 174-174
Yalcinkaya E et al. Alterations in paraoxonase-1 activity. (2013) BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY 0006-9248 1336-0345 114 11 668-668
Macharia M et al. The growing importance of PON1 in cardiovascular health: a review. (2012) JOURNAL OF CARDIOVASCULAR MEDICINE 1558-2027 1558-2035 13 7 443-453
Selek S et al. Effects of gemfibrozil and L-carnitine on PON1 activity, oxidative/anti-oxidative parameters and hepatosteatosis in rabbits feed with fat-rich diet. (2011) KAFKAS UNIVERSITESI VETERINER FAKULTESI DERGISI 1300-6045 1309-2251 17 2 183-190
Saeed SA et al. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. (2008) HEMODIALYSIS INTERNATIONAL 1492-7535 1542-4758 12 4 471-479
Phuntuwate W et al. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. (2008) ATHEROSCLEROSIS 0021-9150 196 1 122-128
Mackness MI et al. The role of paraoxonase 1 activity in cardiovascular disease: Potential for therapeutic intervention. (2004) AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS 1175-3277 1179-187X 4 4 211-217
Tomas M et al. The antioxidant function of high density lipoproteins: A new paradigm in atherosclerosis. (2004) REVISTA ESPANOLA DE CARDIOLOGIA 0300-8932 1579-2242 57 6 557-569
Mackness M et al. Paraoxonase 1 and atherosclerosis: Is the gene or the protein more important?. (2004) FREE RADICAL BIOLOGY AND MEDICINE 0891-5849 1873-4596 37 9 1317-1323
Durrington PN et al. The hunt for nutritional and pharmacological modulators of paraoxonase. (2002) ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 1079-5642 1524-4636 22 8 1248-1250
Audikovszky M et al. Obes betegek lipidprofiljának és paraoxonaz aktivitásának változása orlistat kezelést követően: [Changes in lipid profile and paraoxonase activity in obese patients as a result of orlistat treatment]. (2001) ORVOSI HETILAP 0030-6002 1788-6120 142 50 2779-2783,
1863329
Adeyemi Wale Johnson et al. Comparative evaluation of the pharmacological value of virgin coconut oil, omega 3 fatty acids, and orlistat in experimental study on obesity with normo/hyper-lipidaemic diet. (2020) PHARMANUTRITION 2213-4344 13
Kiortsis DN et al. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. (2005) DIABETE & METABOLISME (1975-1995) 0338-1684 31 1 15-22
Ferretti Gianna et al. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. (2015) PROGRESS IN LIPID RESEARCH 0163-7827 60 50-73
Macharia M et al. The growing importance of PON1 in cardiovascular health: a review. (2012) JOURNAL OF CARDIOVASCULAR MEDICINE 1558-2027 1558-2035 13 7 443-453
Mackness MI et al. The role of paraoxonase 1 activity in cardiovascular disease: Potential for therapeutic intervention. (2004) AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS 1175-3277 1179-187X 4 4 211-217
Mackness M et al. Paraoxonase 1 and atherosclerosis: Is the gene or the protein more important?. (2004) FREE RADICAL BIOLOGY AND MEDICINE 0891-5849 1873-4596 37 9 1317-1323
Durrington PN et al. The hunt for nutritional and pharmacological modulators of paraoxonase. (2002) ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 1079-5642 1524-4636 22 8 1248-1250
Balogh Z et al. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?. (2001) DIABETES & METABOLISM 1262-3636 27 5 604-610,
1300013
Moya Carlos et al. Paraoxonases: metabolic role and pharmacological projection. (2018) NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 0028-1298 1432-1912 391 4 349-359
Choi Siu Wai et al. Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?. (2018) REDOX REPORT 1351-0002 1743-2928 23 1 1-24
Yurttas Leyla et al. Synthesis and evaluation of novel 2-[(1,2,4-triazol-3-yl)thio]acetamide derivatives as potential serum paraoxonase-1 (PON1) activators. (2017) MARMARA ECZACILIK DERGISI / MARMARA PHARMACEUTICAL JOURNAL 1309-0801 21 4 967-977
Saheblear Amirhossein et al. Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status. (2016) METABOLISM-CLINICAL AND EXPERIMENTAL 0026-0495 1532-8600 65 5 609-622
Triki S. et al. La PON1 est-elle un facteur du risque cardiovasculaire chez les diabétiques de type 2? [Is PON1 a factor of cardiovascular risk in type 2 diabetes?]. (2016) ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE 0003-3928 1768-3181 65 2 81-86
Yoldemir T et al. Association of serum paraoxonase concentration with serum lipid levels and bone mineral density measurements in early postmenopausal women. (2015) CLIMACTERIC 1369-7137 18 3 405-410
Jamuna Rani A et al. Paraoxonase 1 in type 2 diabetes mellitus - A review. (2014) INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH 0976-044X 28 2 175-179
Rosenblat M et al. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: In vitro and in vivo studies. (2012) BIOFACTORS 0951-6433 1872-8081 38 4 292-299
She ZG et al. The Human Paraoxonase Gene Cluster As a Target in the Treatment of Atherosclerosis. (2012) ANTIOXIDANTS & REDOX SIGNALING 1523-0864 1557-7716 16 6 597-632
Macharia M et al. The growing importance of PON1 in cardiovascular health: a review. (2012) JOURNAL OF CARDIOVASCULAR MEDICINE 1558-2027 1558-2035 13 7 443-453
Marija M et al. The influence of gemfibrozil on malondialdehyde level and paraoxonase 1 activity in Wistar and Fisher rats. (2011) BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 1742-7835 1742-7843 108 6 428-435